Clinical trials: Dengue, open to volunteers
Dengue, Chikungunya
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis
- Trial name
- RACSMEI (NCT07358910)
- Where
- Cambodia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
Exanthema, Dengue Fever
Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections
Exanthematous fevers are a global public health problem. The spread of arboviruses due to various factors, including climate change, has resulted in major epidemics such as the one that occurred in Brazil in 2024, representing an…
- Conditions
- Exanthema, Dengue Fever, Chikungunya, Measles
- Trial name
- CRIUS (NCT07112846)
- Volunteers
- 830 people
- Sponsor
- Hospital Israelita Albert Einstein
Dengue
A Study of CP-COV03 Compared With Placebo in Participants With Dengue (Part 1) and Dengue-like Illness (Part 2)
This is a randomized, double-blind, placebo-controlled Phase 2/3 study to evaluate the efficacy, safety, and antiviral activity of CP-COV03 in adult patients with dengue infection.
- Trial name
- NCT07576868
- Testing
- CP-COV03
- Where
- 2 sites in Vietnam
- Volunteers
- 210 people
- Sponsor
- Hyundai Bioscience Co., Ltd.
Dengue
Impact of IIT-SIT on Dengue Clusters
This randomized controlled trial aims to evaluate the efficacy of Wolbachia-infected male mosquitoes combined with sterile insect technique (IIT-SIT) to mitigate active dengue transmission in Singapore.
- Trial name
- NCT06894901
- Testing
- Biological (Male Wolbachia-infected Aedes aegypti)
- Where
- Singapore
- Volunteers
- 900 people
- Sponsor
- National Environment Agency, Singapore
Randomised Clinical Trial, Double Blind
Phase I Study of VLPDEN-02 Dengue Vaccine in Healthy Adults
This is a Phase 1, randomized, double-blind, placebo-controlled, dose escalation study. Forty-two flavivirus-naïve adults will be enrolled and will receive 3 administrations of VLPDEN-02 or control at days 0, 28, and 56.
- Conditions
- Randomised Clinical Trial, Double Blind, Dengue, Challenge Test
- Trial name
- NCT07831473
- Testing
- VLPDEN-02 1.0 µg (0.25 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 10 µg (2.5 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 100 µg (25 µg of each VLP) + ALFQ adjuvant
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- VLP Therapeutics
Dengue, Chikungunya
Effects Of A Rehabilitation Protocol On Muscle Strength, Muscle Fatigue And Postural Control In Post-Dengue And Chikungunya Patients
Introduction: Dengue and Chikungunya arboviral diseases are considered major public health challenges in tropical regions due to high infection rates and the occurrence of musculoskeletal sequelae that impair strength, balance…
- Trial name
- NCT07600879
- Testing
- Exercise
- Where
- Brazil
- Volunteers
- 54 people
- Sponsor
- Universidade do Estado do Pará
Dengue Virus Infection
Dengvaxia US Pregnancy Registry
The primary objective of this study is to assess maternal, obstetrical, pregnancy, and neonatal and infant outcomes among women and their offspring(s) vaccinated with Dengvaxia during their pregnancy
- Trial name
- DNG00044 (NCT04486638)
- Testing
- Dengue Tetravalent Vaccine, Live
- Where
- Puerto Rico
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA)
Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
The goal of this clinical trial is to evaluate whether the live attenuated tetravalent Butantan-Dengue vaccine (Butantan-DV) is safe and capable of inducing an immune response in patients aged 12 to 59 years with autoimmune…
- Conditions
- Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Systemic Lupus Erythematosus (SLE), Juvenile Systemic Lupus Erythematosus
- Trial name
- BTNDV-ARD (NCT07087912)
- Testing
- Dengue 1,2,3,4 (attenuated) vaccine
- Where
- 2 sites in Brazil
- Volunteers
- 477 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Dengue, Sepsis
Immune Responses to Dengue and Sepsis
The goal of this research study is to help the investigators better understand serious dengue disease. The investigators will collect clinical information and up to four blood samples from participants with dengue, influenza…
- Conditions
- Dengue, Sepsis, Influenza
- Trial name
- DEN-SEP (NCT07040202)
- Where
- 4 sites in Cambodia
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
Dengue
Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative)
The goal of this study is to evaluate the efficacy and safety of emetine administered orally for symptomatic patients aged 18-65 years infected with the dengue virus. The main questions it aims to answer are: 1.
- Trial name
- NCT07016321
- Testing
- Emetine Hydrochloride 6mg, Emetine Hydrochloride 12mg
- Where
- 2 sites in United States, Nepal
- Volunteers
- 600 people
- Sponsor
- Johns Hopkins University
Dengue, Montelukast
Efficacy of Montelukast in Preventing Transaminase Elevation in Adult Dengue Patients
The goal of this clinical trial is to learn if drug montelukast works to treat dengue in adults. It will also learn about the safety of drug montelukast .
- Conditions
- Dengue, Montelukast, Transaminases
- Trial name
- NCT06747130
- Testing
- Montelukast
- Where
- Thailand
- Volunteers
- 82 people
- Sponsor
- Phramongkutklao College of Medicine and Hospital
Dengue, Chikungunya
Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years.
This randomized, controlled, double blind trial aims at assessing the safety and immunogenicity profiles of the co-administered Live Attenuated Dengue and Chikungunya vaccines comparatively to the isolated administration, in the…
- Trial name
- NCT06973772
- Testing
- DENGUE: Dengue 1,2,3,4 (attenuated) vaccine CHIKUNGUNYA: Chikungunya (CHIKV) live attenuated vaccine (VLA1555), DENGUE: Dengue 1,2,3,4 (attenuated) vaccine, Chikungunya (CHIKV) live attenuated vaccine (VLA1555)
- Where
- 7 sites in Brazil
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Dengue, Vaccination
Dengue Vaccine Strategy in Children Aged 9 to 17 Years in the French Caribbean
Dengue fever, an arbovirus transmitted by the Aedes mosquito, is a public health problem in all tropical and subtropical regions of the world. There is currently no antiviral treatment and vector control has shown its limits.
- Conditions
- Dengue, Vaccination, Seroprevalence, Infectious Disease
- Trial name
- DengueSEA (NCT04839757)
- Where
- Martinique
- Volunteers
- 590 people
- Sponsor
- University Hospital Center of Martinique
Dengue Fever, Papaya Leaf Extract
To Assess the Efficacy of Carica Papaya Leaf Extract in Improving Platelet Counts Among Pediatric Patients With Dengue-associated Thrombocytopenia
The goal of this clinical trial is to evaluate whether Carica papaya leaf extract (CPLE) can improve platelet counts in children aged 2 to 12 years diagnosed with dengue fever and thrombocytopenia.
- Conditions
- Dengue Fever, Papaya Leaf Extract, Pediatric Patients
- Trial name
- papaya leaf (NCT07172100)
- Testing
- Carica Papaya Leaf Extract Group, standard treatment
- Where
- Pakistan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Ziauddin Hospital
Dengue
Dengue - Sample Collection Study Pakistan
The objective of this study is to collect well-characterized serum and plasma specimens from confirmed dengue positive and dengue negative subjects to support dengue diagnostic products development.
- Trial name
- NCT07203183
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Abbott Rapid Dx
Dengue
Butantan-DV Vaccine in Elderly Populations (DEN-04-IB)
This is a randomized, double-blind (60 -79 years) and open-label (40-59 years), three-arm parallel Phase 3b, multicenter study to evaluate the safety and non-inferiority of the humoral immune response of the Butantan Dengue…
- Trial name
- DEN-04-IB (NCT06891950)
- Testing
- Dengue 1,2,3,4 (attenuated) vaccine
- Where
- 5 sites in Brazil
- Volunteers
- 997 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Dengue Disease, Dengue Haemorrhagic Fever
International Registry of Dengue Infection in Congenital Bleeding Disorders (DengueCBDR)
Dengue fever, a viral infection transmitted by Aedes mosquitoes, is a major health issue in tropical and subtropical regions. Around 20-30% of symptomatic patients developed Dengue Hemorrhagic Fever (DHF), which leads to impaired…
- Conditions
- Dengue Disease, Dengue Haemorrhagic Fever, Dengue Fever, Dengue Fever With Warning Signs
- Trial name
- DengueCBDR (NCT07409857)
- Where
- Thailand
- Volunteers
- 100 people
- Sponsor
- Mahidol University
Safety Issues, Dengue
Safety, Virological and Immunological Assessment of the Controlled Dengue Human Infection Model in Dengue-Immune Participants in Thailand (DHIT-Immune)
rDEN2Δ30-7169 is a dengue challenge strain that previously reports its viremia induction effect in participants with minimal symptoms in US flavivirus naïve participants.
- Conditions
- Safety Issues, Dengue, Viremia, Immune-related Adverse Event
- Trial name
- DHIT-Immune (NCT06908018)
- Testing
- rDEN2Δ30-7169
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Dengue Fever
A Study in Children and Teenagers to Learn if a TDV Dengue Vaccination Lowers the Chance of Hospital Stays for Dengue
The main aim of this study is to collect more information on the effectiveness of TDV when used in a pilot public vaccination program for children and adolescents participating in a community-based cohort in Southeast Asian…
- Trial name
- NCT06843226
- Testing
- No Intervention
- Where
- 7 sites in Indonesia, Malaysia and 1 more
- Volunteers
- 70,000 people, healthy volunteers welcome
- Sponsor
- Takeda
Emerging Infectious Diseases, COVID-19
Smart Analysis and Decision-Making for Emerging Infectious Diseases
Emerging infectious diseases, such as COVID-19, mpox, and dengue fever, are characterized by rapid transmission, wide impact, and high uncertainty, posing ongoing threats to global public health.
- Conditions
- Emerging Infectious Diseases, COVID-19, Influenza, Mpox (Monkeypox)
- Trial name
- SMART-ID (NCT07678619)
- Testing
- Multi-Agent Integrated Smart Toolkit for Emerging Infectious Diseases, Routine Practices
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Peking University